<DOC>
	<DOCNO>NCT01276353</DOCNO>
	<brief_summary>The purpose study compare 23 mg donepezil sustain release ( SR ) currently market formulation 10 mg donepezil immediate release ( IR ) patient severe Alzheimer 's disease .</brief_summary>
	<brief_title>A Study Versus E2020 10mg Followed Open-label Extension Phase Explore Safety E2020 SR 23 mg Japanese Subjects With Severe Alzheimer 's Type Dementia</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Inclusion Criteria Diagnostic evidence probable Alzheimer 's disease ( AD ) consistent Diagnostic Statistical Manual Mental Disordersversion IV ( DSMIV ) Hachinski Ischemic Score Functional Assessment Staging ( FAST ) scale great equal 6 Screening . MiniMental State Examination ( MMSE ) score 1 12 Screening Subjects stable Aricept dose 10 mg immediate release ( IR ) , take single , daily dose 3 month prior Screening Visit Evidence consistent Alzheimer 's disease ( AD ) cranial image magnetic resonance imaging ( MRI ) compute tomography ( CT ) scan etc . obtain within 24 month prior Screening Visit . Subjects observations dementia Alzheimer 's type last image diagnosis reconfirm . Age 50 year Written inform consent obtain subject ( possible ) subject 's legal guardian representative Exclusion Criteria Subjects dementia Alzheimer 's type Subjects significant neurological psychiatric disorder stroke , brain tumor , schizophrenia , epilepsy , normal pressure hydrocephalus , mental retardation , history head injury loss consciousness , history brain surgery follow persistent deficit Subjects allergy donepezil hydrochloride piperidine derivative Subjects cause Alzheimer 's disease ( AD ) support laboratory test Vitamin B12 , folate level , triiodothyronine , free triiodothyronine , thyroxine , thyroid stimulate hormone ( TSH ) serologic test syphilis</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Alzheimer Disease</keyword>
	<keyword>Dementia</keyword>
	<keyword>Delirium</keyword>
	<keyword>Amnestic</keyword>
	<keyword>Cognitive Disorders</keyword>
	<keyword>Donepezil</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Tauopathies</keyword>
	<keyword>Neurodegenerative Diseases</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Cholinesterase Inhibitors</keyword>
	<keyword>Enzy</keyword>
</DOC>